Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, operates as a healthcare company with focus on Canada. The company's products target therapeutic areas such as pain, allergy, and dermatology. It in-licenses and acquires complementary products for Canadian and international markets; and out-licenses select products in global markets. The company operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for treatment of migraine; Bezalip for treatment of hypercholesterolemia Type IIa and IIb mixed hyperlipidemia; Fiorinal for relief from tension-type headache; Visken for treatment of hypertension and prophylaxis of angina pectoris; Viskazide to reduce elevated blood pressure; Soriatane for treatment of severe psoriasis and keratinization disorders; Moviprep for cleansing of the colon as a preparation for colonoscopy; PegaLAX for relieving constipation; Resultz and Lausbub non-prescription products intended to kill head lice and remove their eggs from hair; Suvexx and Treximet for treatment of migraine; Pennsaid, a topical pain product is used to treat signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid; Vimovo for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; Yosprala for secondary prevention of cardiovascular and cerebrovascular events; Synera topical patches to prevent pain of needle sticks into superficial veins and superficial skin procedures; NeoVisc for treatment of pain and joint functionality; Collatamp G for local haemostasis of capillary, parenchymatous, and seeping haemorrhages; and Uracyst for glycosaminoglycans (GAG) replenishment therapy. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuv

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$1.05    OTCQX
As of 01/25/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Index country:  Canada
Country of incorporation:  
IPO date:  06/01/2021
Outstanding shares:  11,388,282
Average volume:  2,291
Market cap:   $11,957,696
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   -0.49
PB ratio:   0.99
PS ratio:   0.17
Return on equity:   409.35%
Net income %:   -35.36%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy